ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 164,11
1,52%
Dow Jones
44 711,43
0,77%
DAX
22 612,02
2,12%
Brent Oil
74,93
-0,21%
Bitcoin
96 809,49
0,20%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ZyVersa Therapeutics Inc (ZVSA)

  7. ZyVersa Therapeutics Inc (ZVSA) Actualités

ZVSA

ZyVersa Therapeutics (ZVSA)

ZyVersa Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ZVSA
DateHeureSourceTitreSymboleSociété
24/01/202522h05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ZVSAZyVersa Therapeutics Inc
17/01/202522h05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ZVSAZyVersa Therapeutics Inc
30/12/202414h30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ZVSAZyVersa Therapeutics Inc
27/12/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ZVSAZyVersa Therapeutics Inc
20/12/202423h04Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ZVSAZyVersa Therapeutics Inc
20/12/202422h15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ZVSAZyVersa Therapeutics Inc
18/12/202413h55GlobeNewswire Inc.ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San FranciscoNASDAQ:ZVSAZyVersa Therapeutics Inc
20/11/202413h55GlobeNewswire Inc.ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical TrialNASDAQ:ZVSAZyVersa Therapeutics Inc
15/11/202414h35GlobeNewswire Inc.Life Sciences Investor Forum: Presentations Now Available for Online ViewingNASDAQ:ZVSAZyVersa Therapeutics Inc
14/11/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
14/11/202414h10GlobeNewswire Inc.ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business UpdateNASDAQ:ZVSAZyVersa Therapeutics Inc
14/11/202414h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZVSAZyVersa Therapeutics Inc
05/11/202413h00GlobeNewswire Inc.ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 DiabetesNASDAQ:ZVSAZyVersa Therapeutics Inc
29/10/202412h57GlobeNewswire Inc.ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss DrugsNASDAQ:ZVSAZyVersa Therapeutics Inc
22/10/202413h57GlobeNewswire Inc.ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative DiseasesNASDAQ:ZVSAZyVersa Therapeutics Inc
17/10/202413h50GlobeNewswire Inc.ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine MonthsNASDAQ:ZVSAZyVersa Therapeutics Inc
15/10/202413h50GlobeNewswire Inc.ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome InhibitorsNASDAQ:ZVSAZyVersa Therapeutics Inc
07/10/202413h55GlobeNewswire Inc.ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic ComplicationsNASDAQ:ZVSAZyVersa Therapeutics Inc
16/09/202423h30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ZVSAZyVersa Therapeutics Inc
09/09/202422h35Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ZVSAZyVersa Therapeutics Inc
09/09/202422h32Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ZVSAZyVersa Therapeutics Inc
09/08/202422h40GlobeNewswire Inc.ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business UpdateNASDAQ:ZVSAZyVersa Therapeutics Inc
07/08/202413h50GlobeNewswire Inc.ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic InflammationNASDAQ:ZVSAZyVersa Therapeutics Inc
29/07/202413h45GlobeNewswire Inc.ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older AdultsNASDAQ:ZVSAZyVersa Therapeutics Inc
25/07/202413h57GlobeNewswire Inc.ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100NASDAQ:ZVSAZyVersa Therapeutics Inc
19/07/202403h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVSAZyVersa Therapeutics Inc
18/07/202417h18GlobeNewswire Inc.ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal ModelNASDAQ:ZVSAZyVersa Therapeutics Inc
09/07/202413h57GlobeNewswire Inc.ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024NASDAQ:ZVSAZyVersa Therapeutics Inc
15/05/202414h35GlobeNewswire Inc.ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business UpdateNASDAQ:ZVSAZyVersa Therapeutics Inc
15/05/202414h25Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:ZVSAZyVersa Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ZVSA

Dernières Valeurs Consultées

NYSE
DIS
Walt Disney
SPI
SP500
S&P 500
NASDAQ
AAPL
Apple
EU
MC
Lvmh Moet Hennessy Louis...
EU
CAP
Capgemini
NASDAQ
AMZN
Amazon.com
EU
PX1
CAC 40
NASDAQ
GOOGL
Alphabet
EU
ORA
Orange
EU
BEL20
Bel 20
NASDAQ
MSFT
Microsoft
EU
ACA
Credit Agricole
COIN
SOLUSD
Solana
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces